Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The First Affiliated Hospital of University of South China
AK104 10mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 10 mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5) is combined with radiotherapy(50Gy/25F) for 2 cycles. Assess disease efficiency( objective response rate; disease control rate; duration of overall response; time to resolve) and safety( adverse event).
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
unresectable locally advanced esophageal squamous cell carcinoma; ECOG PS 0-1; At least one measurable lesion according to RESIST standard 1.1; not received anti-tumor treatment in the past
You may not be if
received immunotherapy in the past; Active hepatitis B, hepatitis C and other infectious diseases; Severe liver and kidney function, cardiovascular and cerebrovascular abnormalities